Condition: Tonsil Cancer · Sponsor: Lund University Hospital
In this trial, patients with early squamous cell carcinoma of the tonsil with clinical stage T1-2 (p16-positive or p16-negative) N0-1 (p16-positive)/N0-N2b (p16-negative) according to American Joint Committee on Cancer (AJCC) 8th edition, aimed for unimodal and ipsilateral treatment with radiotherapy with curative intent will be included. The patients will be randomized to in a 1:1 ratio to receive radiotherapy with either photons (conventional radiotherapy) versus radiotherapy with protons.
This description comes directly from the study's public registry record.
Maria Gebre-Medhin, MD · +46 46 17 75 20 · maria.gebre-medhin@skane.se
Iréne Schönström, RN · +46 46 17 85 59 · irene.schonstrom@skane.se
Always discuss trial participation with your own doctor first.
| Gävle Hospital | Gävle, Sweden | Recruiting |
| Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
| Jönköping Hospital | Jönköping, Sweden | Recruiting |
| Karlstad Hospital | Karlstad, Sweden | Recruiting |
| Linköping University Hospital | Linköping, Sweden | Recruiting |
| Lund University Hospital | Lund, Sweden | Recruiting |
| Örebro University Hospital | Örebro, Sweden | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
| University Hospital | Umeå, Sweden | Recruiting |
| Scandion clinic | Uppsala, Sweden | Recruiting |
| Uppsala Accademical Hospital | Uppsala, Sweden | Recruiting |
| Västmanlands Hospital | Västerås, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03829033